What makes UpToDate so powerful?

  • over 11000 topics
  • 22 specialties
  • 5,700 physician authors
  • evidence-based recommendations
See more sample topics
Find Patient Print
0 Find synonyms

Find synonyms Find exact match

Treatment of insomnia in adults
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
Treatment of insomnia in adults
View in Chinese
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: May 2017. | This topic last updated: May 25, 2017.

INTRODUCTION — Insomnia was previously viewed as a sleep disturbance that was secondary to a medical condition, psychiatric illness, sleep disorder, or medication, and would improve with treatment of the underlying disorder [1]. However, evidence over the past 20 years indicates that this view is incorrect.

It is now recognized that insomnia is often an independent disorder [2,3]. Insomnia may occur in the absence of coexisting conditions and, when coexisting conditions exist, may persist despite successful treatment of the coexisting condition. Treatment directed at the insomnia and the comorbidity may be necessary. Since insomnia can precipitate, exacerbate, or prolong comorbid conditions, treatment of insomnia may improve comorbidities [4-7].

Treatment of insomnia is described in this topic review. The definition, types, epidemiology, clinical features, consequences, and diagnostic evaluation of insomnia are reviewed elsewhere. (See "Overview of insomnia in adults" and "Clinical features and diagnosis of insomnia in adults".)

GENERAL APPROACH — All patients with insomnia should receive therapy for any medical condition, psychiatric illness, substance abuse, or sleep disorder that may be precipitating or exacerbating the insomnia (table 1). They should also receive basic behavioral counseling about sleep hygiene (table 2) and stimulus control (table 3).

For patients who continue to have insomnia that is sufficiently burdensome to warrant other interventions, treatment options include behavioral therapy, medication, or both:

Behavioral therapies beyond sleep hygiene and stimulus control include relaxation, sleep restriction therapy, cognitive therapy, and cognitive behavioral therapy for insomnia (CBT-I) [8]. These therapies are not available in all medical centers. (See 'Behavioral therapy' below.)

Approved medications used to treat insomnia include benzodiazepines, nonbenzodiazepine sedatives, melatonin agonists, doxepin, and suvorexant, an orexin antagonist. (See 'Medications' below.)

Combination therapy involves initially prescribing both CBT-I and a medication (usually for six to eight weeks), then tapering the medication off or to an as-needed schedule while continuing CBT-I (see 'Combination therapy' below). The use of medication prior to the initiation of behavioral therapy appears to be less effective [9].

The choice of treatment should be individualized according to the patient's values and preferences, the availability of advanced behavioral therapies, the severity and impact of the insomnia, and the potential benefits versus the risks, costs, and inconveniences. For most patients, we suggest CBT-I rather than medication as initial therapy, recognizing that both approaches are effective in short-term studies, but that medications have a higher risk of side effects and have been inadequately evaluated for use for longer than a year. However, access to behavioral therapy may be limited in some regions and for some patients groups. A preference for CBT-I or other behavioral therapies over medication as initial therapy has been endorsed in clinical practice guidelines of the American Academy of Sleep Medicine [10], the British Association for Psychopharmacology [11], and the American College of Physicians [8,12].

Treatment decisions must also factor in the potential health risks of untreated chronic insomnia, which include decreased quality of life, increased risk for psychiatric comorbidities and substance abuse, decreased performance, and the association between chronic insomnia and risk of cardiovascular morbidity and all-cause mortality. (See "Overview of insomnia in adults", section on 'Consequences'.)

In clinical practice, initial treatment typically involves sleep hygiene instruction and stimulus control procedures. If follow-up indicates that further treatment is needed, then more formal CBT-I alone or in combination with a medication may be used for six weeks. For patients who respond to therapy (ie, report both improved sleep at night and improvement of daytime deficits), the medication can be tapered or used as needed while continuing the CBT-I. Patients whose symptoms recur after discontinuation of therapy may require re-evaluation for referral for polysomnography or additional CBT-I, with or without pharmacologic therapy. An exception to this approach is patients who have short-term insomnia due to a self-limited stressor; such patients may benefit from short-term medication alone.

BEHAVIORAL THERAPY — Behavioral therapies for insomnia include sleep hygiene education, stimulus control, relaxation, sleep restriction therapy, cognitive therapy, and cognitive behavioral therapy [8]. Patients whose insomnia has been successfully treated by behavioral therapy are likely to report decreased daytime symptoms and improvement of daytime function, quality of life, and comorbidities. Behavioral therapy is well tolerated and has a low risk of adverse effects, but it is not readily available in many places.

Behavioral therapy beyond an introduction to sleep hygiene and stimulus control is typically implemented over a series of approximately 6 to 10 sessions. The evidence suggests that the success of the therapy is related to the experience of the individual implementing it [13].

Sleep hygiene — Sleep hygiene refers to actions that tend to improve and maintain good sleep (table 2) [14]:

Sleep as long as necessary to feel rested (usually seven to eight hours for adults) and then get out of bed

Maintain a regular sleep schedule, particularly a regular wake-up time in the morning

Try not to force sleep

Avoid caffeinated beverages after lunch

Avoid alcohol near bedtime (eg, late afternoon and evening)

Avoid smoking or other nicotine intake, particularly during the evening

Adjust the bedroom environment as needed to decrease stimuli (eg, reduce ambient light, turn off the television or radio)

Avoid prolonged use of light-emitting screens (laptops, tablets, smartphones, ebooks) before bedtime [15]

Resolve concerns or worries before bedtime

Exercise regularly for at least 20 minutes, preferably more than four to five hours prior to bedtime [16,17]

Avoid daytime naps, especially if they are longer than 20 to 30 minutes or occur late in the day

Sleep hygiene counseling alone has not been directly compared with no intervention or a sham intervention. However, numerous clinical trials have used sleep hygiene counseling alone as the control intervention and showed some improvement in sleep but less than that seen with pharmacotherapy or cognitive behavioral therapy [18-20].

Stimulus control — Patients with insomnia may associate their bed and bedroom with the fear of not sleeping or other arousing events, rather than the more pleasurable anticipation of sleep. The longer one stays in bed trying to sleep, the stronger the association becomes. This perpetuates the difficulty falling asleep.

Stimulus control therapy is a strategy whose purpose is to disrupt this association by enhancing the likelihood of sleep (table 3) [21]. Patients should not go to bed until they are sleepy and should use the bed primarily for sleep (and not for reading, watching television, eating, or worrying). They should not spend more than 20 minutes in bed awake. If they are awake after 20 minutes, they should leave the bedroom and engage in a relaxing activity, such as reading or listening to soothing music. Patients should not engage in activities that stimulate them or reward them for being awake in the middle of the night, such as eating or watching television. In addition, they should not return to bed until they are tired and feel ready to sleep. If they return to bed and still cannot sleep within 20 minutes, the process should be repeated. An alarm should be set to wake the patient at the same time every morning, including weekends. Daytime naps are not allowed.

Patients may not improve immediately. However, accumulating sleepiness will facilitate sleep during successive nights.

Stimulus control therapy has improved sleep in randomized trials and its effects may be long lasting [22-24]. One study suggested that stimulus control therapy is more effective among patients who are not already taking medications for insomnia [25].

Relaxation — Relaxation therapy may be implemented before each sleep period. There are two common techniques for relaxation therapy: progressive muscle relaxation and the relaxation response.

Progressive relaxation is based upon the theory that an individual can learn to relax one muscle at a time until the entire body is relaxed. Beginning with the muscles in the face, the muscles are contracted gently for one to two seconds and then relaxed. This is repeated several times. The same technique is used for other muscle groups, usually in the following sequence: jaw and neck, upper arms, lower arms, fingers, chest, abdomen, buttocks, thighs, calves, and feet. This cycle is repeated for approximately 45 minutes, if necessary.

The relaxation response begins by lying or sitting comfortably. The eyes are closed and relaxation is allowed to spread throughout the body. A relaxed, abdominal breathing pattern is established. Thoughts are redirected away from everyday thoughts and toward a neutral mental focusing device, such as a peaceful word or image.

One trial randomly assigned 57 patients with insomnia to receive progressive relaxation therapy or no therapy [26]. Progressive relaxation therapy improved measures of sleep, but not daytime function. Another randomized trial similarly found improvement in sleep measures among patients who received relaxation therapy compared with a sham therapy, but the improvement was modest and smaller than that achieved with cognitive behavioral therapy [27]. Slow-paced breathing prior to sleep onset as a means of reducing vagal activity has been shown to improve sleep parameters [28].

Sleep restriction therapy — Some patients with insomnia stay in bed longer to try to make up for lost sleep. This causes a circadian shift and a reduction in the homeostatic drive that makes sleep onset the following night more difficult and results in the need to stay in bed even longer. Sleep restriction therapy counteracts this tendency by limiting the total time allowed in bed, including naps and other sleep periods outside of bed, in order to increase the drive to sleep [29]. This consolidates sleep and improves sleep efficiency (the percentage of time in bed that the patient is asleep).

Sleep restriction therapy begins by decreasing the time spent in bed to the same amount of time that the patient reports sleeping (usually determined from sleep diaries or logs completed by the patient), but not less than five hours per night (table 4). On a daily basis, the patient reports the amount of sleep obtained the previous night and the amount of time spent in bed. The clinician then computes the sleep efficiency, which is the reported time asleep divided by the reported time in bed. The time in bed is increased by 15 to 30 minutes once the sleep efficiency exceeds 85 percent. This process is repeated until the patient reports improved sleep without residual daytime sleepiness. However, total time in bed for some patients can remain at six hours or less for long periods of time. Naps are not permitted.

To improve compliance, the rationale for the therapy needs to be carefully explained to patients and some care needs to be used to determine and schedule the time in bed in a manner that maximizes the ability to sleep and is acceptable to the patient. Older patients tend to have more difficulty maintaining sleep even when restricted; therefore, they are given more lenient criteria.

A 2014 systematic review identified four randomized trials of sleep restriction therapy as a stand-alone therapy versus another intervention or control for chronic insomnia [30]. The weighted effect sizes for improvement in subjective sleep variables were medium to large and comparable to those achieved with cognitive behavioral interventions in other meta-analyses [31,32]. In the largest individual study, 179 older adults with primary insomnia were randomly assigned to six weeks of sleep restriction therapy, stimulus control therapy, a multicomponent behavioral intervention, or wait-list control [33]. All treatments resulted in significant improvements in diary-reported sleep outcomes compared with control, and there was no advantage to a multicomponent intervention over a single component intervention. Effect sizes were generally moderate to large and maintained at 3 and 12 months post-treatment.

Potential adverse effects of sleep restriction therapy include increased daytime sleepiness and decreased reaction times, as well as possible exacerbation of bipolar disorder. (See 'Adverse effects' below.)

Cognitive therapy — Patients who are awake at night commonly become concerned that they will perform poorly the next day if they do not obtain adequate sleep. This worry can exacerbate their difficulty falling asleep, creating a vicious cycle of wakefulness and concern. A person may begin to blame all negative events in their life on poor sleep. During cognitive therapy, a person works with a therapist to deal with anxiety and catastrophic thinking, while establishing realistic expectations related to insomnia and the need for sleep.

Cognitive behavioral therapy — Cognitive behavioral therapy for insomnia (CBT-I) is a strategy that combines several of the previously described approaches over several weeks [34]. A sample eight-session CBT-I program may include an introductory sleep education session, followed by two sessions that focus on stimulus control and sleep restriction. These may be followed by two sessions that focus on cognitive therapy and then a session on sleep hygiene. Finally, there may be a session that reviews and integrates the previous session and a session that addresses future problems, such as stress and relapse [35]. Patients are encouraged to complete sleep logs as they learn and apply the various strategies. This allows improvement to be measured.

The advantage of the educational nature of CBT-I is that it provides patients with tools to apply in the future. Disadvantages of CBT-I include the duration of therapy and the relatively few clinicians who are skilled at all of its components. The benefit of CBT-I may be reduced when it is administered by less experienced clinicians [13].

CBT-I has proven efficacious in moderate- to high-quality randomized trials [1,36,37]. A 2015 meta-analysis identified 20 randomized trials of CBT-I for chronic insomnia in over 1100 participants; CBT-I approaches incorporated at least three of the following: cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation [37]. Compared with inactive control conditions, CBT-I improved sleep on a variety of outcome measures, including sleep onset latency (improved by 19 minutes), wake time after sleep onset (decreased by 26 minutes), and sleep efficiency (improved by 10 percent). The benefits of CBT-I appeared to persist beyond the active treatment period. Separate meta-analyses of trials in patients with insomnia comorbid with medical, sleep, or psychiatric disorders have found similar results [38,39].

Several randomized studies have suggested that alternative delivery methods such as telephone-based CBT-I [40,41] and internet-based CBT-I [42-47] may be effective treatment options that could overcome some of the access and economic barriers that exist for traditional CBT-I. As an example, one trial recruited 303 patients with chronic insomnia via the internet and randomly assigned them to receive a six-week interactive, fully automated web-based CBT-I program or a control condition (access to an educational website) [46]. At six weeks, patients assigned to CBT-I showed greater improvement in subjective sleep measures, including 41 percent who achieved remission of insomnia (Insomnia Severity Index <8). Remission rates also favored the intervention at one year (57 versus 27 percent), although subjective total sleep times were similar between groups.

Despite these results, larger studies are needed that directly compare alternative delivery methods with face-to-face CBT-I [48]. In a small trial comparing face-to-face and guided online CBT-I with a wait-list control in 90 patients with insomnia, both delivery methods performed significantly better than the wait-list control, but face-to-face CBT-I was associated with larger treatment effects and better depression and anxiety outcomes than online delivery [49].

CBT-I is particularly recommended for use in patients where medications are contraindicated or may be more likely to produce side effects, such as in older adults, pregnant women, or patients with renal, hepatic, or pulmonary disease.

Other approaches — Other behavioral therapies that may emerge as useful in the treatment of insomnia include mindfulness meditation [50-53] and exercise training [54]. However, a small randomized trial comparing tai chi with CBT-I in older adults found that CBT-I was associated with greater and more sustained improvement in sleep quality, fatigue, and depressive symptoms than tai chi [55].

Adverse effects — Adverse effects of behavioral therapy have not been well described, but one area of caution relates to sleep restriction. Sleep restriction decreases sleep latency and increases sleep efficiency by causing sleep deprivation (ie, total sleep time is decreased, not increased). In one study, subjects reported increased sleepiness and had slower reaction times during a four-week treatment period that then returned to baseline three months later, when time in bed had increased to about seven hours [56]. These effects are similar to those seen during chronic partial sleep deprivation and suggest that patients using this therapy should be carefully monitored and instructed to avoid hazardous activity and driving when time in bed has been significantly reduced. Sleep restriction should be used with caution in patients with underlying bipolar disorder, since sleep deprivation can trigger manic episodes [57].


Choice of an agent — Medications or classes of medications that are approved to treat insomnia include benzodiazepines, nonbenzodiazepine hypnotics, melatonin agonists, doxepin, and suvorexant [58,59]. Although all of these agents or classes have been shown to be more effective than placebo at improving short-term sleep outcomes, the magnitude of effect is variable; most trials have been industry sponsored, raising concerns about publication bias; and confidence in the overall estimation of risk-to-benefit ratio is low [59]. The potential benefits of pharmacologic therapy on sleep quality and daytime function are balanced against the risk of side effects as well as physical and psychological addiction with long-term use. These risks may be increased in certain clinical settings:

Pregnancy – Sedative-hypnotics may increase the risk of fetal malformations if used during the first trimester.

Alcohol consumption – Sedative-hypnotics should not be combined with alcohol because there is a risk of excessive sedation and respiratory suppression whenever central nervous system suppressants are combined.

Renal or hepatic disease – Most sedative-hypnotic medications undergo hepatic and renal clearance. Metabolic clearance may be delayed in patients who have renal or hepatic disease, leading to accumulation and excessive sedation.

Pulmonary disease or sleep apnea – Many sedative-hypnotics are respiratory suppressants that can worsen obstructive sleep apnea or hypoventilation.

Nighttime decision makers – Sedative-hypnotics should not be taken by individuals who may be called upon to make important decisions during the night (eg, clinicians on-call or single parents responsible for the care of young children) because they can cause excess sedation and impair decision-making.

Older adults – The risk of adverse effects is increased in older adults, especially those who are older than 75 years. This is a consequence of multiple comorbidities and central nervous system changes associated with aging. (See 'Older adults' below.)

Randomized trials directly comparing the effect of different medications on insomnia are rare. Indirect comparisons of benzodiazepines and nonbenzodiazepines suggest that these classes of medication have a similar impact on sleep onset latency (ie, they decrease objective sleep onset latency by approximately 10 minutes and subjective sleep onset latency by 15 to 20 minutes) [60]. However, the benzodiazepines are more likely to prolong total sleep time, perhaps because they tend to have longer half-lives [60,61].

In one of the few trials that directly compared different medications, 382 patients with primary insomnia received each of six interventions in random order for two nights each, with a three- to seven-day wash-out period in between [62]. The agents included placebo, eszopiclone (1, 2, 2.5, and 3 mg), and zolpidem (10 mg). Compared with placebo, eszopiclone at doses of 2.5 and 3 mg decreased the median wake time after sleep onset, but zolpidem and eszopiclone at doses of 1 and 2 mg did not. The wake time after sleep onset refers to the amount of time that the patient is awake between sleep onset and the final morning arising time. There were no differences in any of the objective sleep outcomes when eszopiclone (2 and 3 mg) and zolpidem were compared directly.

When selecting among various sedative-hypnotic medications, we suggest choosing on the basis of the type of insomnia (ie, sleep onset or sleep maintenance) and the duration of effect:

For patients with sleep onset insomnia, a short-acting medication is a reasonable choice for an initial trial of pharmacologic therapy. This may improve the insomnia with less residual somnolence the following morning. Examples of short-acting medications (duration of effect ≤8 hours) include zaleplon, zolpidem, triazolam, lorazepam, and ramelteon.

For patients with sleep maintenance insomnia, a longer-acting medication is preferable for an initial trial of pharmacologic therapy. Examples of longer-acting medications include zolpidem extended release, eszopiclone, temazepam, estazolam, low dose doxepin, and suvorexant. However, these medications may increase the risk for hangover sedation and patients must be warned about this possibility.

For patients with awakening in the middle of the night, both zaleplon and a specific sublingual tablet form of zolpidem have been developed for use during the night, with the constraint that there will be at least four hours of time in bed remaining after administration.

Other issues to be considered when prescribing a medication for insomnia include cost and adverse effects. The benzodiazepines and older nonbenzodiazepines (specifically, zaleplon and zolpidem) tend to be less expensive than the other nonbenzodiazepines and ramelteon. The adverse effects are discussed below. (See 'Risks and side effects' below.)

Benzodiazepines — Benzodiazepines are a class of sleep promoting medications that bind to several gamma-aminobutyric acid (GABA) type A receptor subtypes [63]. They reduce the time to the onset of sleep, prolong stage 2 sleep, prolong total sleep time, and may slightly reduce the relative amount of rapid eye movement (REM) sleep [64]. In addition, they decrease anxiety, impair memory, and have anticonvulsive properties.

Benzodiazepines commonly used for the treatment of insomnia include triazolam, estazolam, lorazepam, temazepam, flurazepam, and quazepam. A primary difference among these medications is their duration of action. Triazolam is short acting; estazolam, lorazepam, and temazepam are intermediate acting; flurazepam and quazepam are long acting (table 5) [64]. Diazepam is also long acting, but is generally not used to treat insomnia because it has a long duration of effect and can lead to the accumulation of active metabolites. The long-acting benzodiazepines should be avoided in older adults because there is increased risk for adverse effects in this patient population [65].

Meta-analyses of randomized, placebo-controlled trials indicate that benzodiazepines decrease sleep latency and the number of awakenings, while improving sleep duration and sleep quality [60,61,66,67]. Typical changes associated with these medications include decreases in the duration to sleep onset by approximately 10 minutes and increases in the total sleep time of 30 to 60 minutes [60,61].

The side effects of benzodiazepines are described below. (See 'Risks and side effects' below.)

Nonbenzodiazepines — Nonbenzodiazepine benzodiazepine receptor agonists have a structure that is different from the benzodiazepines and includes more targeted action at one GABA type A receptor. A consequence of their greater specificity is less anxiolytic and anticonvulsant activity.

Nonbenzodiazepines appear to improve both subjective and objective sleep outcomes. Specifically, meta-analyses of randomized, placebo-controlled trials indicate that nonbenzodiazepines decrease sleep latency and the number of awakenings, while improving sleep duration and sleep quality [58,60,61,66-68]. Nonbenzodiazepines have increased adverse events compared with placebo.

Nonbenzodiazepines commonly used to treat insomnia include zaleplon, zolpidem, eszopiclone, and zolpidem extended release (table 6):

Zaleplon has a very short half-life of about one hour. As a result, it is effective for patients who have difficulty falling asleep (ie, sleep onset insomnia), but may not be effective for patients who have difficulty maintaining sleep (ie, sleep maintenance insomnia) [69]. Due to the very short half-life, the potential for hangover sleepiness is minimal after normal sleep periods. Occasional side effects include headache, dizziness, nausea, abdominal pain, and somnolence [63]. Zaleplon is not indicated for long-term use.

Zolpidem has a half-life of approximately 1.5 to 2.4 hours. It is indicated for the short-term treatment of insomnia characterized by difficulty with sleep initiation [70]. The most common side effects are headache, dizziness, and somnolence, which can in turn lead to falls. Zolpidem is not approved for long-term use.

Zolpidem is also available in a dissolvable tablet and as an oral spray for patients who have difficulty swallowing a pill. A dissolvable tablet (1.75 to 3.5 mg) can be taken in the middle of the night for sleep maintenance insomnia, with the requirement that at least four hours be available to sleep after administration and at least five hours be available prior to driving. In January of 2013, the US Food and Drug Administration (FDA) issued a safety announcement recommending use of a lower dose in women than had been previously recommended [71]. This should also be considered in men. (See 'Dosing precautions' below.)

Zolpidem extended release also has a half-life of about 1.5 to 2.4 hours, but is released over a longer duration. It was developed to improve both sleep onset insomnia and sleep maintenance insomnia while avoiding hangover effects, although it has never been directly compared with regular zolpidem [72]. Side effects of zolpidem extended release are relatively few, with the most common being headache, somnolence, and dizziness, which can in turn lead to falls [63]. In January of 2013, the FDA recommended use of a lower dose in women than had been previously recommended [71]. This lower dose should also be considered for men. In a follow-up safety announcement, the FDA added a warning that patients should not drive or engage in other activities that require complete mental alertness the day after taking zolpidem extended release because zolpidem levels can remain high enough the next day to impair these activities [73].

Sleep may be worse during the first night following discontinuation of this medicine. Zolpidem extended release is not limited to short-term use and there is little evidence for abuse or dependence in most patients. In theory, however, such medications could be habit forming with long-term use. (See 'Adverse effects of nonbenzodiazepines' below.)

Eszopiclone has the longest half-life of the approved nonbenzodiazepines, approximately five to seven hours. This may extend to nine hours in older adult patients. Eszopiclone is effective for both sleep onset insomnia and sleep maintenance insomnia [74]. Patients taking eszopiclone may report an unpleasant metallic taste. Other reported side effects are shared with nonbenzodiazepines as a class (headache, dizziness, parasomnias, next-day impairment in some patients) [63,75]. (See 'Adverse effects of nonbenzodiazepines' below.)

Sleep may be worse on the first night after discontinuation of this medication. Eszopiclone is not limited to short-term use and there is little evidence for abuse or dependence in most patients. In theory, however, such medications could be habit forming with long-term use.

Most clinical trials evaluated short-term therapy (eg, seven days), although a few longer clinical trials have been performed. In one randomized trial, patients treated with eszopiclone for six months had improved quality of life, decreased work limitation, and improved sleep compared with placebo [76]. This persisted throughout the trial and the subsequent six month open label extension. In another randomized trial of 1018 patients with insomnia, zolpidem extended release taken for up to six months improved sleep onset, sleep maintenance, morning sleepiness, next-day concentration, and work performance compared with placebo [77,78].

Adverse effects associated with the nonbenzodiazepines are similar to those associated with benzodiazepines. This is discussed below. (See 'Risks and side effects' below.)

Melatonin agonists — Ramelteon is a melatonin agonist. In randomized trials, short-term use of ramelteon is associated with improvement in sleep onset in patients with insomnia, but the effect size is relatively small and may not be clinically significant [59].

A 2014 meta-analysis that included 11 trials and over 5700 patients found that ramelteon was associated with significant improvement in subjective sleep latency (-4.6 minutes) and total sleep time (7.3 minutes) compared with placebo but no significant difference in other parameters, including subjective total sleep time, number of awakenings, and wakefulness after sleep onset [79]. Although most studies examined short-term treatment and outcome in middle-aged adults [79], a small number of individual trials have demonstrated persistence of subjective benefit for at least six months, and improvement in older adults [80-84]. Subjective efficacy extended to one year in an open label trial [85].

Although ramelteon is approved in the United States and Japan, the European Medicines Agency (EMA) concluded in 2008 that there was inadequate evidence that the drug was effective for insomnia [86]. It did not approve ramelteon for use. Tasimelteon is a second melatonin agonist that has been approved in the United States for treatment of non-24-hour sleep-wake disorder, a circadian sleep-wake rhythm disorder that occurs primarily in blind individuals [87,88].

Ramelteon binds to melatonin receptors expressed in the suprachiasmatic nucleus with much higher affinity than melatonin itself and has a half-life of 1.5 to 5 hours [89,90]. Ramelteon is metabolized by the liver and should be used with caution in patients with hepatic insufficiency. It is contraindicated in patients taking fluvoxamine, since fluvoxamine may decrease the metabolism of ramelteon [91]. Ramelteon is more effective in treating sleep onset insomnia compared with sleep maintenance insomnia.

Adverse effects associated with melatonin agonists are generally milder than those associated with benzodiazepines and nonbenzodiazepines. The most common adverse effect is somnolence. (See 'Adverse effects of melatonin agonists' below.)

Orexin receptor antagonists — Orexin receptor antagonists are a novel class of drugs in development for the treatment of insomnia. Orexin A and orexin B are hypothalamic neuropeptides that play a key role in promoting wakefulness and regulating the sleep-wake cycle [92]. Suvorexant, an oral dual orexin receptor antagonist with a 12-hour half-life, was approved by the FDA in August 2014 [93].

The efficacy of suvorexant was demonstrated in a multicenter international trial of 781 patients with primary insomnia who were randomly assigned to receive nightly suvorexant or placebo in a 2:1 ratio for one year, followed by a two-month randomized discontinuation phase [94]. The dose of suvorexant used was 40 mg for patients <65 years of age and 30 mg for patients ≥65 years. At one month, patients treated with suvorexant had improved subjective total sleep time (39 versus 16 minutes; difference 23 minutes, 95% CI 16-29) and subjective time to sleep onset (-18 versus -8 minutes, 95% CI -15 to -5) compared with placebo. Two-thirds of patients in each arm completed one year of treatment; improvements in subjective sleep persisted at one year. The most common adverse effect was somnolence, which was more common in patients treated with suvorexant than placebo (13 versus 3 percent). There was a trend toward rebound insomnia with discontinuation of suvorexant. A smaller trial showed similar results with short-term treatment and evidence of a dose-response gradient in both efficacy and side effects with doses ranging from 10 to 80 mg nightly [95].

In next-day driving performance testing, some men and women treated with 20 mg of suvorexant had impaired driving performance, including 5 out of 52 subjects who stopped testing early due to somnolence, and the FDA has approved suvorexant at a maximum dose of 20 mg per night [93,96]. Treatment should be initiated at the lowest dose (5 mg), so that the lowest effective dose can be determined. Suvorexant is metabolized by cytochrome P450 3A4 (CYP3A4), and there is potential for increased toxicity when used in combination with CYP3A4 inhibitors (table 7). The recommended dose of suvorexant is 5 mg in patients taking moderate CYP3A4 inhibitors, and it is not recommended for use in combination with strong CYP3A4 inhibitors. Due to the potential for dependence and abuse, it is a schedule C-IV controlled substance. The most common side effect is daytime somnolence. Like other sedatives, it has the potential to worsen sleep-disordered breathing in vulnerable patients. (See 'Adverse effects of orexin antagonists' below.)

The role for this drug in the treatment of insomnia remains to be determined, as suvorexant and other similar drugs in development have not yet been compared directly with other therapies for insomnia. Development of almorexant, another orexin receptor antagonist, was halted in 2011 for reasons that have not been made publicly available [97].

Other medications — Numerous other medications have a sedating effect, but are not recommended for routine use in patients with insomnia. These include antidepressants, diphenhydramine, antipsychotics, and barbiturates.

Antidepressants — One antidepressant, doxepin, has been approved by the FDA at doses of 3 and 6 mg primarily for the treatment of insomnia. Other antidepressants (eg, amitriptyline, trazodone) are sedating because of central anticholinergic or antihistaminergic activity. Such antidepressants may be useful in the management of patients who have insomnia associated with depression, although they are not approved by the FDA for treatment of insomnia.

Sedating antidepressants have also been evaluated in patients with insomnia who are not depressed in a few studies:

In a trial that randomly assigned 240 older adult patients with insomnia to receive low dose doxepin (1 or 3 mg) or placebo for 12 weeks, patients who received the 3 mg dose of doxepin had a reduction of wake time after sleep onset, increased total sleep time, increased sleep efficiency, and increased self-reported sleep quality when compared with placebo. Patients who received the 1 mg dose of doxepin had inconsistent improvement of some outcomes measures at several time points [98].

Another trial randomly assigned 306 nondepressed patients with insomnia to receive trazodone, zolpidem, or placebo for two weeks [99]. After one week of therapy, trazodone improved subjective sleep latency, sleep duration, wake time after sleep onset, and number of awakenings, compared with placebo. However, after two weeks, the trazodone group did not differ significantly from the placebo group.

Despite their sleep-promoting effects, the routine use of sedating antidepressants other than low dose doxepin to treat insomnia in patients who are not depressed has not been recommended because the sedating effect tends to be short-lived and other side effects are common [1,100]. The American Academy of Sleep Medicine (AASM) practice guideline includes doxepin among the drugs listed as options for management sleep maintenance in chronic insomnia but suggests against use of trazodone based on paucity of data and the small effect sizes observed in the single randomized trial [59].

Diphenhydramine — Many over-the-counter sleep aids contain diphenhydramine (a sedating antihistamine) or a combination of diphenhydramine plus pain relievers. There is little evidence that diphenhydramine improves insomnia and it may cause sedation the next day (due to its long half-life). Additional side effects include decreased alertness, diminished cognitive function, delirium, dry mouth, blurred vision, urinary retention, constipation, and increased intraocular pressure [1]. Routine use of diphenhydramine to treat insomnia is not recommended [59].

Antipsychotics — Antipsychotics have been used to treat insomnia. However, there are few trials that demonstrate effectiveness of these medications and all have potentially significant adverse effects. The routine use of antipsychotics to treat insomnia in patients without psychosis is not recommended [1].

Barbiturates — Barbiturates have similarly been used to treat insomnia. However, all have potentially significant adverse effects. Routine use of barbiturates to treat insomnia is not recommended [1].

Over-the-counter — Herbal products, hormones, and alcoholic beverages have been used as sleep aids by patients with insomnia but there are sparse data upon which to evaluate their efficacy. These agents are not regulated by the FDA.

Herbal products – A variety of herbal products are purported to be useful for insomnia. There is little evidence from randomized controlled trials about the efficacy of many herbals, however, and for those that have been well studied (eg, valerian), there is little evidence of benefit. A meta-analysis that included 14 randomized trials in over 1600 patients found no significant difference between any herbal medicine and placebo on any of 13 clinical efficacy measures of insomnia [101]. The majority of the trials (11 out of 14) studied valerian; chamomile, kava, and wuling were studied in one trial each. Unlike the other herbals studied, valerian was associated with a greater number of adverse events per person compared with placebo. Valerian may also produce hepatotoxic effects [1]. Contamination with undesirable substances poses a problem for many such natural remedies. (See "Overview of herbal medicine and dietary supplements".)

Melatonin – Melatonin is a hormone that is normally secreted by the pineal gland. It is not recommended as a treatment for insomnia in most patients [59], except when sleep disturbances are due to delayed sleep-wake phase syndrome (a circadian sleep-wake rhythm disorder) [1,59,102-107]. It appears to be safe when used short-term (three months or less) [104]. (See "Delayed sleep-wake phase disorder", section on 'Management'.)

Alcohol – Alcohol is commonly self-prescribed as a sleep aid because it decreases the time required to fall asleep, at least in the short-term. However, alcohol can promote sleep disturbances later in the night and promotes upper airway instability and sleep apnea. These negative effects, coupled with the significant risk of dependence and interaction with other medications, preclude the use of alcohol to treat insomnia [108]. (See "Insomnia in patients with a substance use disorder", section on 'Alcohol'.)

Risks and side effects

Common to all hypnotics — The most common adverse effects associated with the benzodiazepines and nonbenzodiazepines are residual daytime sedation, drowsiness, dizziness, lightheadedness, cognitive impairment, motor incoordination, and dependence [1,60,61,66]. In addition, most hypnotics are respiratory suppressants that can worsen obstructive sleep apnea or hypoventilation.

Long-term use may be habit forming and rebound insomnia may occur when some short-acting medications are discontinued. Less common adverse effects include complex sleep-related behaviors (eg, sleep walking, driving, making telephone calls, eating, or having sex while not fully awake), anterograde amnesia (particularly with triazolam or when used with alcohol), aggressive behavior, and severe allergic reaction [64,109]. Lethal overdose is possible [110], particularly with concurrent use of alcohol or another central nervous system depressant. (See 'Suicide risk' below.)

Adverse effects of nonbenzodiazepines — Generally speaking, the adverse effects associated with the nonbenzodiazepines are similar to those associated with the benzodiazepines, but their frequency and severity may be less [60,61]. This is probably related to their shorter half-lives, although as discussed below, next-morning impairment has been increasingly recognized with higher doses and in certain patient populations. (See 'Dosing precautions' below.)

Most of the complex sleep-related behaviors that have been reported in patients taking nonbenzodiazepines were related to zolpidem, but it is unknown whether this reflects the widespread use of zolpidem or an association between the agent and the side effect [64]. In one study, zolpidem accounted for 12 percent of all emergency department visits for adverse drug events related to psychiatric medication in the United States over the period of 2009 to 2011, and 21 percent of all such visits involving adults ≥65 years of age [111]. Other side effects that have been reported in patients taking nonbenzodiazepines include an unpleasant taste (eszopiclone) and hallucinations (zolpidem).

The incidence of infection (eg, upper respiratory, otitis media, urinary tract, conjunctivitis, others) may also be increased among patients taking a nonbenzodiazepine, according to one meta-analysis [112]. Two subsequent studies, one in humans and one in mice, have also reported an increased risk of pneumonia associated with benzodiazepines and the nonbenzodiazepine zopiclone, possibly related to modification of GABA type A activity during infection [113,114]. A study in mice suggested that this risk could extend to all hypnotics that act at this site [114].

Dosing precautions — Dosing recommendations for hypnotic medications have traditionally been based on group statistical effects rather than individual responses. However, there has been increasing recognition that variability in nonbenzodiazepine metabolism may affect next-morning drug levels and side effects. The safety announcements reviewed below suggest that clinicians should have increased sensitivity to next-day residual effects when prescribing any of the drugs in this class and should educate patients accordingly.

In 2013, the FDA published a safety communication that the recommended dose for zolpidem be set at the lowest dose (5 mg for all except zolpidem extended release, which is now 6.25 mg) for women and also be considered for men [71]. In addition, a new warning was issued for zolpidem extended release, advising that individuals refrain from driving or other activities that require mental alertness the day after taking the drug [73]. These recommendations were based on studies showing that blood levels of zolpidem above about 50 ng/mL appeared capable of impairing driving sufficiently to increase the risk of an accident. This blood level was found in about 15 percent of women and 3 percent of men eight hours after administration of 10 mg of zolpidem. Eight hours after use of the extended-release formulation of zolpidem, 33 percent of women and 25 percent of men still had this elevated blood level.

Additional recommendations were not made for older adults, who have previously been advised to use the lowest doses of these medications, but additional care is warranted for these patients. (See 'Older adults' below.)

In 2014, a similar safety communication was issued for eszopiclone, based on data that the 2 and 3 mg doses may be associated with impairment of driving skills, memory, and coordination lasting more than 11 hours without subjective awareness in some patients [115]. A starting dose of 1 mg is now recommended in all patients.

Adverse effects of melatonin agonists — Ramelteon has fewer side effects than the nonbenzodiazepines or benzodiazepines [116]. It is not associated with hypnotic side effects (eg, next day residual performance deficits), withdrawal, or rebound insomnia, and it does not appear to be habit forming [84,116]. Ramelteon has little abuse potential and is not a scheduled substance with the United States Drug Enforcement Administration (DEA), unlike most other drugs used to treat insomnia. The most common side effects are somnolence, dizziness, nausea, fatigue, and headache [1,64]. Elevated prolactin levels and decreased testosterone levels may occur, but routine monitoring of either is not indicated in the absence of other clinical indications.

Adverse effects of orexin antagonists — The most common adverse effects of suvorexant are daytime somnolence and headache. As with other hypnotics, next-day driving may be impaired due to the long half-life of the drug [117]. Other potential side effects include sleepwalking, REM sleep behavior disorder (RBD), suicidal ideation, and the emergence of sleep paralysis, hypnogogic hallucinations, and mild cataplexy (as seen in narcolepsy). Risk of RBD is likely highest in patients with Parkinson disease and other alpha-synucleinopathies, which are known to be associated with RBD [118]. (See "Rapid eye movement sleep behavior disorder".)

Suvorexant is metabolized by cytochrome P450 3A4 (CYP3A4), and there is potential for increased toxicity when used in combination with CYP3A4 inhibitors (table 7).

Limited data suggest that suvorexant has relatively minor effects on the severity of sleep-disordered breathing in vulnerable patients [119,120], although like other sedatives, it should be used cautiously in these patients until there is more experience with the drug. In a sleep laboratory study, 26 patients with mild to moderate obstructive sleep apnea were given 40 mg of suvorexant or placebo for four consecutive nights in a crossover design, and the mean apnea-hypopnea index (AHI) increased by a mean of 2.7 (95% CI 0.2-5.1) after multiple doses of suvorexant [120]. The AHI rose by ≥5 events per hour in eight patients (range 5 to 20) and decreased by ≥5 events in three patients.  

Older adults — Older adults have a particularly high risk of adverse effects from hypnotic drugs, including excessive sedation, cognitive impairment, delirium, night wandering, agitation, postoperative confusion, balance problems, and impaired performance of daily activities [121-123]. An increased risk of falls with severe consequences, including traumatic brain injury and hip fracture, has been observed in association with both benzodiazepines and nonbenzodiazepines such as zolpidem [122,124].

In a meta-analysis of 24 randomized trials (2417 patients) that evaluated the impact of pharmacotherapy in adults older than 60 years with insomnia, there was an improvement of sleep quality, total sleep time, and frequency of nighttime awakening [125]. However, the magnitude of these benefits was relatively small compared with the two- to fivefold increase in adverse cognitive or psychomotor events. This suggests that additional caution is necessary when deciding whether pharmacotherapy is indicated for an older patient with insomnia.

Mortality — Several observational studies have found an association between use or prescription of hypnotic drugs and all-cause mortality and/or cancer, with adjusted hazard ratios ranging from 1.1 to 4.5 [126-131]. The association has been observed in the general adult population [126-128,130,131], postmenopausal women [129], and in patients with schizophrenia [132]. Other studies in older adults have failed to find a significant association between hypnotic use and mortality after adjusting for potential confounders [133,134].

One of the larger studies suggested that hypnotic drugs (including frequently prescribed agents such as zolpidem and temazepam) were associated with an increased risk of both cancer and death, even at prescription levels of less than 18 doses per year over a 2.5-year duration [126]. Another large retrospective case-control study included over 34,000 patients age 16 years and older first prescribed an anxiolytic or hypnotic drug or both between 1998 and 2001, matched by age, gender, and primary care practice with nearly 70,000 controls [131]. Over an average follow-up period of 7.6 years, prescription of anxiolytic and hypnotic drugs was associated with a twofold increased hazard of death after adjusting for a wide range of potential confounders, including medical and psychiatric comorbidities, sleep disorders, and other drugs. After excluding deaths during the first year of follow-up, this effect translated to four excess deaths per 100 people followed over a seven-year period.

The associations found in these observational studies do not indicate causality, however. Chronic insomnia has been associated with a variety of medical and psychiatric comorbidities, many of which are associated with premature mortality, and it is difficult to exclude residual confounding by indication or other unmeasured factors. A prospective investigation of long-term hypnotic use compared with placebo and behavioral treatment is needed.

Suicide risk — Insomnia itself is associated with increased risk for suicide, which may be primarily mediated by underlying depression [135]. Whether prescription of a hypnotic drug in patients with insomnia modifies the risk of suicidality is not conclusively known. Randomized trials in patients with insomnia have not found a difference in suicidality in patients treated with hypnotics compared with placebo. Although generally reassuring, the quality of this data is limited by low numbers of observed events, exclusion of patients with preexisting depression or history of suicidality in most trials, and short-term follow up.

A 2017 systematic review identified several retrospective and prospective observational studies showing a positive association between suicidality and use of hypnotics but concluded that none of the studies adequately controlled for depression or other psychiatric disorders that may be linked with insomnia [136]. Other studies suggest that treating insomnia in patients with depression in some cases hastens recovery from depression [4,137], and in other cases at least improves insomnia and next-day functioning, if not necessarily impacting depression severity [138,139].

In the United States, most hypnotics carry warnings or cautions about suicide risk in patients with depression. While not studied or validated formally, safe prescribing practices that may help to mitigate risk of suicide and other risks include using the lowest possible effective dose to control symptoms, avoiding concurrent use of alcohol and other sedatives, and regular follow-up to assess drug efficacy, side effects, and ongoing need for medication (table 8) [136]. Patients with comorbid depression should be assessed for suicidal ideation before prescribing hypnotics and if present, monitored closely while considering other treatment options for insomnia. (See "Unipolar depression in adults: Assessment and diagnosis", section on 'Suicide risk' and "Suicidal ideation and behavior in adults", section on 'Patient evaluation'.)

Drug interactions — Concurrent use of any sleeping medication and alcohol (or another central nervous system depressant) increases the risk of central nervous system depression and, therefore, is contraindicated.

Most benzodiazepines (except lorazepam, oxazepam, and temazepam) and nonbenzodiazepines are metabolized by the CYP3A4 system [64]. Inhibitors of the CYP3A4 system (eg, clarithromycin) increase the risk of toxicity related to benzodiazepines and nonbenzodiazepines, while inducers of the CYP3A4 system (eg, rifampin) may decrease the effectiveness of benzodiazepines and nonbenzodiazepines.

Ramelteon is metabolized by the CYP1A2 system and, to a lesser extent, the CYP2C9 and CYP3A4 systems [64]. Fluvoxamine is a potent inhibitor of the CYP1A2 system and should not be used with ramelteon because it markedly increases serum concentrations of ramelteon. Other inhibitors of the CYP1A2 (eg, ciprofloxacin), CYP2C9, or CYP3A4 systems may also increase the risk of ramelteon toxicity, while inducers of the CYP systems (eg, rifampin) may decrease the effectiveness of ramelteon.

Suvorexant is metabolized by the CYP3A system and should not be administered in combination with strong inhibitors of CYP3A (eg, ketoconazole, many antiretroviral drugs) (table 7). Conversely, suvorexant effects can be decreased when co-administered with strong CYP3A inducers (eg, rifampin, carbamazepine, phenytoin).

COMBINATION THERAPY — Combination therapy involves prescribing both cognitive behavioral therapy for insomnia (CBT-I) and a medication, usually for six to eight weeks. The medication is then tapered off or to an as-needed schedule, while continuing the CBT-I.

Two trials from the same investigators illustrate the effects of combination therapy:

The first trial randomly assigned 78 patients with persistent insomnia to receive CBT-I alone, temazepam alone, CBT-I plus temazepam, or placebo for eight weeks [140]. At the end of the treatment phase, all of the therapies had significantly decreased the wake time after sleep onset compared with placebo, although there were no significant differences when the treatment groups were compared with each other. Two years following the completion of treatment, only the CBT-I alone group had maintained its reduction in the wake time after initial sleep onset.

The second trial randomly assigned 160 patients with persistent insomnia to receive CBT-I plus zolpidem or CBT-I alone for six weeks [141]. Both groups had decreased sleep onset latency, decreased wake time after sleep onset, and increased sleep efficiency when compared with baseline after six weeks. However, there was no significant difference in the remission rate when the groups were compared with each other (44 versus 39 percent). The patients then underwent secondary randomization. Patients in the CBT-I alone group were randomly assigned to no treatment or maintenance CBT-I, while patients in the CBT-I plus zolpidem group were randomly assigned to either maintenance CBT-I or maintenance CBT-I plus as-needed zolpidem. The improvement of sleep latency, wake time after sleep onset, and sleep efficiency was maintained in all groups at 6, 12, and 24 months, with slight advantage to maintenance CBT-I without continued use of zolpidem as needed [142].

Taken together, the evidence indicates that CBT-I alone, drug therapy alone, and combination therapy all improve measures of insomnia (eg, wake time after sleep onset) within weeks of initiating the therapy. Continuing CBT-I alone after the completion of initial therapy appears to be the best option for maintaining improvement long-term. CBT-I also increases the likelihood that the medication can eventually be tapered [143].

If sleep restriction therapy is combined with hypnotic medication, clinicians should be aware that the combination of chronic partial sleep deprivation and medication hangover could significantly increase daytime sleepiness and behavioral risk. (See 'Adverse effects' above.)

The evidence is insufficient to justify combination therapy as routine initial management for insomnia patients. Many patients will improve with CBT-I alone, without pharmacologic therapy.

FOLLOW-UP — If the treatment is successful, patients will report both improved sleep at night and improvement of daytime deficits. Discontinuation of the medication should be considered in any patient who is receiving pharmacologic therapy alone or combination therapy.

Patients who have little improvement during the initial trial of cognitive behavioral therapy, pharmacologic therapy, or combination therapy may have other causes of poor sleep. Adherence with the prescribed therapy should be confirmed and then additional diagnostic evaluation performed. Such patients often require referral to a sleep disorders center to be evaluated for sleep apnea or other underlying causes. Such an evaluation is indicated earlier (ie, prior to the failure of routine therapy) if there is clinical suspicion that sleep apnea or another etiology exists. (See "Clinical features and diagnosis of insomnia in adults", section on 'Other sleep disorders'.)

Other patients may respond initially to pharmacologic therapy but later relapse while still taking the same drug. In such cases, clinical re-evaluation is warranted to determine whether there are lifestyle changes or other new factors that may be exacerbating the insomnia. There are limited data on tolerance and cross-tolerance among various medications used to treat insomnia, but some amount of tolerance likely exists for the benzodiazepines and nonbenzodiazepine receptor agonists [144-146].

Treatment decisions in patients with possible tolerance must be individualized, taking into account factors such as side effects, duration of therapy, prior therapies, and availability of alternative options, such as behavioral therapy. If lifestyle changes and other exacerbating factors have been ruled out, we consider the following approaches:

In a patient who complains of loss of efficacy from a short-acting nonbenzodiazepine, such as zolpidem, we suggest a trial of a longer-acting drug, such as eszopiclone, or switch to medication from a different class, such as low-dose doxepin.

Some patients may benefit from a drug holiday, after which time they may again respond to the initial drug therapy.

Institution of behavioral therapy can help transition some patients away from long-term use of a benzodiazepine or nonbenzodiazepine receptor agonist. (See 'Behavioral therapy' above.)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topic (see "Patient education: Insomnia (The Basics)")

Beyond the Basics topics (see "Patient education: Insomnia (Beyond the Basics)" and "Patient education: Insomnia treatments (Beyond the Basics)")


All patients with insomnia should receive therapy for any medical condition, psychiatric illness, substance abuse, or sleep disorder that may be precipitating or exacerbating the insomnia. They should also receive general behavioral suggestions, particularly advice regarding sleep hygiene (table 2) and stimulus control (table 3). (See 'General approach' above.)

For patients who continue to have insomnia that is severe enough to require an intervention, we suggest cognitive behavioral therapy for insomnia (CBT-I) as the initial therapy rather than medication (Grade 2B). An alternative type of behavioral therapy is reasonable if CBT-I is not available. (See 'General approach' above and 'Behavioral therapy' above.)

For patients whose insomnia continues to be severe enough to require an intervention despite CBT-I, we suggest the addition of a medication to CBT-I rather than changing to a strategy of medication alone (Grade 2B). (See 'General approach' above and 'Medications' above.)

For patients who require medication for sleep onset insomnia, we suggest a short-acting medication rather than a longer-acting agent (Grade 2C). (See 'Choice of an agent' above.)

For patients who require medication for sleep maintenance insomnia, we suggest a longer-acting medication rather than a short-acting agent (Grade 2C). Alternatively, a formulation of zolpidem has been approved for use in the middle of the night. Patients should be warned about the risk for daytime drowsiness, impaired driving, dizziness, and lightheadedness. (See 'Choice of an agent' above.)

Patients given behavioral plus pharmacologic therapy should continue behavioral therapy for six to eight weeks. In patients who respond to therapy, the medication can be tapered while continuing the behavioral therapy. Patients whose symptoms recur may require evaluation in a sleep disorders center, prior to the institution of long-term therapy. (See 'General approach' above and 'Follow-up' above.)

Long-term treatment with medication alone is not the optimal treatment strategy for patients with insomnia. (See 'Risks and side effects' above.)

Use of UpToDate is subject to the Subscription and License Agreement.


  1. National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005; 28:1049.
  2. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998; 158:1099.
  3. Krystal AD. Psychiatric comorbidity: the case for treating insomnia. Sleep Med Clin 2006; 1:359.
  4. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006; 59:1052.
  5. Roehrs T, Hyde M, Blaisdell B, et al. Sleep loss and REM sleep loss are hyperalgesic. Sleep 2006; 29:145.
  6. Tashjian RZ, Banerjee R, Bradley MP, et al. Zolpidem reduces postoperative pain, fatigue, and narcotic consumption following knee arthroscopy: a prospective randomized placebo-controlled double-blinded study. J Knee Surg 2006; 19:105.
  7. Sack RL, Auckley D, Auger RR, et al. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review. Sleep 2007; 30:1484.
  8. Brasure M, Fuchs E, MacDonald R, et al. Psychological and Behavioral Interventions for Managing Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Ann Intern Med 2016; 165:113.
  9. Vallières A, Morin CM, Guay B. Sequential combinations of drug and cognitive behavioral therapy for chronic insomnia: an exploratory study. Behav Res Ther 2005; 43:1611.
  10. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008; 4:487.
  11. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010; 24:1577.
  12. Qaseem A, Kansagara D, Forciea MA, et al. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med 2016; 165:125.
  13. Espie CA, MacMahon KM, Kelly HL, et al. Randomized clinical effectiveness trial of nurse-administered small-group cognitive behavior therapy for persistent insomnia in general practice. Sleep 2007; 30:574.
  14. Stepanski EJ, Wyatt JK. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev 2003; 7:215.
  15. Chang AM, Aeschbach D, Duffy JF, Czeisler CA. Evening use of light-emitting eReaders negatively affects sleep, circadian timing, and next-morning alertness. Proc Natl Acad Sci U S A 2015; 112:1232.
  16. Hartescu I, Morgan K, Stevinson CD. Increased physical activity improves sleep and mood outcomes in inactive people with insomnia: a randomized controlled trial. J Sleep Res 2015; 24:526.
  17. Tan X, Alén M, Wiklund P, et al. Effects of aerobic exercise on home-based sleep among overweight and obese men with chronic insomnia symptoms: a randomized controlled trial. Sleep Med 2016; 25:113.
  18. Guilleminault C, Clerk A, Black J, et al. Nondrug treatment trials in psychophysiologic insomnia. Arch Intern Med 1995; 155:838.
  19. Edinger JD, Sampson WS. A primary care "friendly" cognitive behavioral insomnia therapy. Sleep 2003; 26:177.
  20. Chen HY, Chiang CK, Wang HH, et al. Cognitive-behavioral therapy for sleep disturbance in patients undergoing peritoneal dialysis: a pilot randomized controlled trial. Am J Kidney Dis 2008; 52:314.
  21. Bootzin RR, Perlis ML. Nonpharmacologic treatments of insomnia. J Clin Psychiatry 1992; 53 Suppl:37.
  22. Pallesen S, Nordhus IH, Kvale G, et al. Behavioral treatment of insomnia in older adults: an open clinical trial comparing two interventions. Behav Res Ther 2003; 41:31.
  23. Espie CA, Lindsay WR, Brooks DN, et al. A controlled comparative investigation of psychological treatments for chronic sleep-onset insomnia. Behav Res Ther 1989; 27:79.
  24. Engle-Friedman M, Bootzin RR, Hazlewood L, Tsao C. An evaluation of behavioral treatments for insomnia in the older adult. J Clin Psychol 1992; 48:77.
  25. Riedel B, Lichstein K, Peterson BA, et al. A comparison of the efficacy of stimulus control for medicated and nonmedicated insomniacs. Behav Modif 1998; 22:3.
  26. Means MK, Lichstein KL, Epperson MT, Johnson CT. Relaxation therapy for insomnia: nighttime and day time effects. Behav Res Ther 2000; 38:665.
  27. Edinger JD, Wohlgemuth WK, Radtke RA, et al. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA 2001; 285:1856.
  28. Tsai HJ, Kuo TB, Lee GS, Yang CC. Efficacy of paced breathing for insomnia: enhances vagal activity and improves sleep quality. Psychophysiology 2015; 52:388.
  29. Spielman AJ, Yang C, Glovinsky PB. Insomnia: Sleep restriction therapy. In: Insomnia Diagnosis and Treatment, Sateia MJ, Buysse DJ (Eds), Informa UK Ltd, London 2010. p.277.
  30. Miller CB, Espie CA, Epstein DR, et al. The evidence base of sleep restriction therapy for treating insomnia disorder. Sleep Med Rev 2014; 18:415.
  31. Montgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2003; :CD003161.
  32. Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol 2006; 25:3.
  33. Epstein DR, Sidani S, Bootzin RR, Belyea MJ. Dismantling multicomponent behavioral treatment for insomnia in older adults: a randomized controlled trial. Sleep 2012; 35:797.
  34. Smith MT, Neubauer DN. Cognitive behavior therapy for chronic insomnia. Clin Cornerstone 2003; 5:28.
  35. Morin CM. Insomnia Psychological Assessment and Management, The Guilford Press, New York 1993.
  36. McCurry SM, Logsdon RG, Teri L, Vitiello MV. Evidence-based psychological treatments for insomnia in older adults. Psychol Aging 2007; 22:18.
  37. Trauer JM, Qian MY, Doyle JS, et al. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163:191.
  38. Geiger-Brown JM, Rogers VE, Liu W, et al. Cognitive behavioral therapy in persons with comorbid insomnia: A meta-analysis. Sleep Med Rev 2015; 23:54.
  39. Wu JQ, Appleman ER, Salazar RD, Ong JC. Cognitive Behavioral Therapy for Insomnia Comorbid With Psychiatric and Medical Conditions: A Meta-analysis. JAMA Intern Med 2015; 175:1461.
  40. Arnedt JT, Cuddihy L, Swanson LM, et al. Randomized controlled trial of telephone-delivered cognitive behavioral therapy for chronic insomnia. Sleep 2013; 36:353.
  41. Bastien CH, Morin CM, Ouellet MC, et al. Cognitive-behavioral therapy for insomnia: comparison of individual therapy, group therapy, and telephone consultations. J Consult Clin Psychol 2004; 72:653.
  42. Vincent N, Lewycky S. Logging on for better sleep: RCT of the effectiveness of online treatment for insomnia. Sleep 2009; 32:807.
  43. Ritterband LM, Thorndike FP, Gonder-Frederick LA, et al. Efficacy of an Internet-based behavioral intervention for adults with insomnia. Arch Gen Psychiatry 2009; 66:692.
  44. van Straten A, Emmelkamp J, de Wit J, et al. Guided Internet-delivered cognitive behavioural treatment for insomnia: a randomized trial. Psychol Med 2014; 44:1521.
  45. Holmqvist M, Vincent N, Walsh K. Web- vs. telehealth-based delivery of cognitive behavioral therapy for insomnia: a randomized controlled trial. Sleep Med 2014; 15:187.
  46. Ritterband LM, Thorndike FP, Ingersoll KS, et al. Effect of a Web-Based Cognitive Behavior Therapy for Insomnia Intervention With 1-Year Follow-up: A Randomized Clinical Trial. JAMA Psychiatry 2017; 74:68.
  47. Zachariae R, Lyby MS, Ritterband LM, O'Toole MS. Efficacy of internet-delivered cognitive-behavioral therapy for insomnia - A systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 2016; 30:1.
  48. Espie CA. "Stepped care": a health technology solution for delivering cognitive behavioral therapy as a first line insomnia treatment. Sleep 2009; 32:1549.
  49. Lancee J, van Straten A, Morina N, et al. Guided Online or Face-to-Face Cognitive Behavioral Treatment for Insomnia: A Randomized Wait-List Controlled Trial. Sleep 2016; 39:183.
  50. Ong J, Sholtes D. A mindfulness-based approach to the treatment of insomnia. J Clin Psychol 2010; 66:1175.
  51. Gross CR, Kreitzer MJ, Reilly-Spong M, et al. Mindfulness-based stress reduction versus pharmacotherapy for chronic primary insomnia: a randomized controlled clinical trial. Explore (NY) 2011; 7:76.
  52. Britton WB, Haynes PL, Fridel KW, Bootzin RR. Mindfulness-based cognitive therapy improves polysomnographic and subjective sleep profiles in antidepressant users with sleep complaints. Psychother Psychosom 2012; 81:296.
  53. Ong JC, Manber R, Segal Z, et al. A randomized controlled trial of mindfulness meditation for chronic insomnia. Sleep 2014; 37:1553.
  54. Yang PY, Ho KH, Chen HC, Chien MY. Exercise training improves sleep quality in middle-aged and older adults with sleep problems: a systematic review. J Physiother 2012; 58:157.
  55. Irwin MR, Olmstead R, Carrillo C, et al. Cognitive behavioral therapy vs. Tai Chi for late life insomnia and inflammatory risk: a randomized controlled comparative efficacy trial. Sleep 2014; 37:1543.
  56. Kyle SD, Miller CB, Rogers Z, et al. Sleep restriction therapy for insomnia is associated with reduced objective total sleep time, increased daytime somnolence, and objectively impaired vigilance: implications for the clinical management of insomnia disorder. Sleep 2014; 37:229.
  57. Kaplan KA, Harvey AG. Behavioral treatment of insomnia in bipolar disorder. Am J Psychiatry 2013; 170:716.
  58. Wilt TJ, MacDonald R, Brasure M, et al. Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Ann Intern Med 2016; 165:103.
  59. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2017; 13:307.
  60. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007; 22:1335.
  61. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000; 162:225.
  62. Erman MK, Zammit G, Rubens R, et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med 2008; 4:229.
  63. Lieberman JA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Prim Care Companion J Clin Psychiatry 2007; 9:25.
  64. Drugs for insomnia. Treat Guidel Med Lett 2009; 7:23.
  65. Bloom HG, Ahmed I, Alessi CA, et al. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc 2009; 57:761.
  66. Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997; 278:2170.
  67. Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev 2009; 13:265.
  68. Huedo-Medina TB, Kirsch I, Middlemass J, et al. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012; 345:e8343.
  69. Elie R, Rüther E, Farr I, et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry 1999; 60:536.
  70. Ambien (zolpidem tartrate) prescribing information. Available at: http://products.sanofi-aventis.us/ambien/ambien.html (Accessed on June 27, 2009).
  71. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm334738.htm.
  72. Hindmarch I, Legangneux E, Stanley N, et al. A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Clin Pharmacol 2006; 62:538.
  73. http://www.fda.gov/Drugs/DrugSafety/ucm352085.htm.
  74. Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005; 6:487.
  75. Ancoli-Israel S, Krystal AD, McCall WV, et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep 2010; 33:225.
  76. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007; 30:959.
  77. Krystal AD, Erman M, Zammit GK, et al. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008; 31:79.
  78. Erman M, Guiraud A, Joish VN, Lerner D. Zolpidem extended-release 12.5 mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial. Sleep 2008; 31:1371.
  79. Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med 2014; 15:385.
  80. Mini LJ, Wang-Weigand S, Zhang J. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother 2007; 5:177.
  81. Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007; 3:495.
  82. Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007; 23:1005.
  83. Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006; 7:312.
  84. Mayer G, Wang-Weigand S, Roth-Schechter B, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009; 32:351.
  85. Richardson GS, Zammit G, Wang-Weigand S, Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry 2009; 70:467.
  86. http://www.emea.europa.eu/htms/human/opinion/opinion.htm (Accessed on January 28, 2009).
  87. Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr Opin Investig Drugs 2009; 10:691.
  88. Lockley SW, Dressman MA, Licamele L, et al. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet 2015; 386:1754.
  89. Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004; 5:523.
  90. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48:301.
  91. Cajochen C. TAK-375 Takeda. Curr Opin Investig Drugs 2005; 6:114.
  92. Mieda M, Sakurai T. Overview of orexin/hypocretin system. Prog Brain Res 2012; 198:5.
  93. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm409950.htm.
  94. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13:461.
  95. Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 2012; 79:2265.
  96. Vermeeren A, Sun H, Vuurman EF, et al. On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers. Sleep 2015; 38:1803.
  97. Riemann D, Spiegelhalder K. Orexin receptor antagonists: a new treatment for insomnia? Lancet Neurol 2014; 13:441.
  98. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep 2010; 33:1553.
  99. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazadone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 1998; 13:191.
  100. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66:469.
  101. Leach MJ, Page AT. Herbal medicine for insomnia: A systematic review and meta-analysis. Sleep Med Rev 2015; 24:1.
  102. Almeida Montes LG, Ontiveros Uribe MP, Cortés Sotres J, Heinze Martin G. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study. J Psychiatry Neurosci 2003; 28:191.
  103. Baskett JJ, Wood PC, Broad JB, et al. Melatonin in older people with age-related sleep maintenance problems: a comparison with age matched normal sleepers. Sleep 2001; 24:418.
  104. Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005; 20:1151.
  105. Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004; 116:91.
  106. Zhdanova IV, Wurtman RJ, Regan MM, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001; 86:4727.
  107. van Geijlswijk IM, Korzilius HP, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep 2010; 33:1605.
  108. Mendelson WB. Hypnotic medications: mechanisms of action and pharmacologic effects. In: Principles and practice of sleep medicine, Kryger M, Roth T, Dement WC (Eds), Saunders, Philadelphia 2005. p.444.
  109. FDA requests label change for all sleep disorder drug products. FDA News. Released on March 14, 2007 http://www.fda.gov/bbs/topics/NEWS/2007/NEW01587.html (Accessed on February 26, 2008).
  110. Buckley NA, Dawson AH, Whyte IM, O'Connell DL. Relative toxicity of benzodiazepines in overdose. BMJ 1995; 310:219.
  111. Hampton LM, Daubresse M, Chang HY, et al. Emergency department visits by adults for psychiatric medication adverse events. JAMA Psychiatry 2014; 71:1006.
  112. Joya FL, Kripke DF, Loving RT, et al. Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med 2009; 5:377.
  113. Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax 2013; 68:163.
  114. Sanders RD, Godlee A, Fujimori T, et al. Benzodiazepine augmented γ-amino-butyric acid signaling increases mortality from pneumonia in mice. Crit Care Med 2013; 41:1627.
  115. www.fda.gov/Drugs/DrugSafety/ucm397260.htm (Accessed on May 27, 2014).
  116. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005; 66 Suppl 9:31.
  117. Farkas R. Suvorexant safety and efficacy. US Food and Drug Administration 2014. Available at: http://www.fda.gov/downloads/.../UCM354215.pdf (Accessed on December 14, 2015).
  118. Tabata H, Kuriyama A, Yamao F, et al. Suvorexant-Induced Dream Enactment Behavior in Parkinson Disease: A Case Report. J Clin Sleep Med 2017; 13:759.
  119. Sun H, Palcza J, Rosenberg R, et al. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respir Med 2015; 109:416.
  120. Sun H, Palcza J, Card D, et al. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. J Clin Sleep Med 2016; 12:9.
  121. Gray SL, LaCroix AZ, Hanlon JT, et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc 2006; 54:224.
  122. Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17:825.
  123. Kudoh A, Takase H, Takahira Y, Takazawa T. Postoperative confusion increases in elderly long-term benzodiazepine users. Anesth Analg 2004; 99:1674.
  124. Tom SE, Wickwire EM, Park Y, Albrecht JS. Nonbenzodiazepine Sedative Hypnotics and Risk of Fall-Related Injury. Sleep 2016; 39:1009.
  125. Glass J, Lanctôt KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005; 331:1169.
  126. Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open 2012; 2:e000850.
  127. Hausken AM, Skurtveit S, Tverdal A. Use of anxiolytic or hypnotic drugs and total mortality in a general middle-aged population. Pharmacoepidemiol Drug Saf 2007; 16:913.
  128. Belleville G. Mortality hazard associated with anxiolytic and hypnotic drug use in the National Population Health Survey. Can J Psychiatry 2010; 55:558.
  129. Hartz A, Ross JJ. Cohort study of the association of hypnotic use with mortality in postmenopausal women. BMJ Open 2012; 2.
  130. Kripke DF, Klauber MR, Wingard DL, et al. Mortality hazard associated with prescription hypnotics. Biol Psychiatry 1998; 43:687.
  131. Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014; 348:g1996.
  132. Tiihonen J, Suokas JT, Suvisaari JM, et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 2012; 69:476.
  133. Gisev N, Hartikainen S, Chen TF, et al. Mortality associated with benzodiazepines and benzodiazepine-related drugs among community-dwelling older people in Finland: a population-based retrospective cohort study. Can J Psychiatry 2011; 56:377.
  134. Vinkers DJ, Gussekloo J, van der Mast RC, et al. Benzodiazepine use and risk of mortality in individuals aged 85 years or older. JAMA 2003; 290:2942.
  136. McCall WV, Benca RM, Rosenquist PB, et al. Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA. Am J Psychiatry 2017; 174:18.
  137. McCall WV, Blocker JN, D'Agostino R Jr, et al. Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. J Clin Sleep Med 2010; 6:322.
  138. Fava M, Asnis GM, Shrivastava RK, et al. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry 2011; 72:914.
  139. Fava M, Schaefer K, Huang H, et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry 2011; 72:473.
  140. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999; 281:991.
  141. Morin CM, Vallières A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA 2009; 301:2005.
  142. Beaulieu-Bonneau S, Ivers H, Guay B, Morin CM. Long-Term Maintenance of Therapeutic Gains Associated With Cognitive-Behavioral Therapy for Insomnia Delivered Alone or Combined With Zolpidem. Sleep 2017; 40.
  143. Baillargeon L, Landreville P, Verreault R, et al. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial. CMAJ 2003; 169:1015.
  144. Aranko K, Mattila MJ, Nuutila A, Pellinen J. Benzodiazepines, but not antidepressants or neuroleptics, induce dose-dependent development of tolerance to lorazepam in psychiatric patients. Acta Psychiatr Scand 1985; 72:436.
  145. Sanger DJ, Zivkovic B. Investigation of the development of tolerance to the actions of zolpidem and midazolam. Neuropharmacology 1987; 26:1513.
  146. Aranko K. Task-dependent development of cross-tolerance to psychomotor effects of lorazepam in man. Acta Pharmacol Toxicol (Copenh) 1985; 56:373.
Topic 7691 Version 57.0

Topic Outline



All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.